首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   15779篇
  免费   994篇
  国内免费   435篇
耳鼻咽喉   85篇
儿科学   310篇
妇产科学   165篇
基础医学   1488篇
口腔科学   210篇
临床医学   1377篇
内科学   1729篇
皮肤病学   186篇
神经病学   703篇
特种医学   384篇
外国民族医学   1篇
外科学   1014篇
综合类   2010篇
预防医学   1183篇
眼科学   97篇
药学   5096篇
  3篇
中国医学   804篇
肿瘤学   363篇
  2023年   176篇
  2022年   264篇
  2021年   434篇
  2020年   408篇
  2019年   349篇
  2018年   351篇
  2017年   363篇
  2016年   366篇
  2015年   370篇
  2014年   851篇
  2013年   916篇
  2012年   904篇
  2011年   1042篇
  2010年   821篇
  2009年   741篇
  2008年   816篇
  2007年   819篇
  2006年   677篇
  2005年   613篇
  2004年   567篇
  2003年   480篇
  2002年   371篇
  2001年   301篇
  2000年   334篇
  1999年   281篇
  1998年   200篇
  1997年   260篇
  1996年   205篇
  1995年   229篇
  1994年   188篇
  1993年   148篇
  1992年   177篇
  1991年   144篇
  1990年   165篇
  1989年   128篇
  1988年   148篇
  1987年   124篇
  1986年   119篇
  1985年   167篇
  1984年   159篇
  1983年   90篇
  1982年   155篇
  1981年   117篇
  1980年   101篇
  1979年   105篇
  1978年   68篇
  1977年   86篇
  1976年   78篇
  1975年   54篇
  1973年   48篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction.  相似文献   
2.
3.
4.
5.
目的:探讨荧光免疫层析法(fluorescence immunochromatography assay,FICA)与酶联免疫吸附法(ELISA)检测英夫利西单抗(infliximab,IFX)血药浓度结果的相关性与一致性。方法:采用已上市的IFX药物浓度测定试剂盒(荧光免疫层析法)与实验室建立的检测IFX浓度的ELISA方法测定克罗恩病患者血液样本IFX浓度。通过Spearman相关分析、Passing-Bablok回归、单样本t检验、Bland-Altman散点图和Cohen's Kappa系数等对检测结果统计分析。结果:共收集到44份血液样本,FICA和ELISA法检测IFX结果的Spearman系数为0.87(P<0.01)。Passing-Bablok回归分析显示,FICA和ELISA法检测IFX结果的回归方程为CFICA=0.5071CELISA+0.6230。单样本t检验提示2种方法检测IFX结果差值与0有显著差异。Bland-Altman散点图显示FICA与ELISA法所测IFX血药浓度的差值中有91.43%(32/35)在一致性界限内(差值均值±1.96 SD)。对2种分析方法检测IFX结果定性分析表明一致性为68.18%(30/44),Cohen's KAppa系数为0.51。结论:FICA与ELISA法检测IFX结果高度相关,但一致性存在差异。ELISA法所测IFX浓度结果高于FICA,提示运用IFX检测结果进行临床决策时要关注检测方法。  相似文献   
6.
《Dental materials》2022,38(7):1083-1098
ObjectiveThe objective of this study was to determine the effect of two plasma surface treatments on the biologic responses of PEEK medical implants manufactured by fused filament fabrication (FFF) 3D printing technology.MethodsThis study created standard PEEK samples using an FFF 3D printer. After fabrication, half of the samples were polished to simulate a smooth PEEK surface. Then, argon (Ar) or oxygen (O2) plasma was used to modify the bioactivity of FFF 3D printed and polished PEEK samples. Scanning electron microscopy (SEM) and a profilometer were used to determine the microstructure and roughness of the sample surfaces. The wettability of the sample surface was assessed using a drop shape analyzer (DSA) after plasma treatment and at various time points following storage in a closed environment. Cell adhesion, metabolic activity, proliferation, and osteogenic differentiation of SAOS-2 osteoblasts were evaluated to determine the in vitro osteogenic activity.ResultsSEM analysis revealed that several spherical nanoscale particles and humps appeared on sample surfaces following plasma treatment. The wettability measurement demonstrated that plasma surface treatment significantly increased the surface hydrophilicity of PEEK samples, with only a slight aging effect found after 21 days. Cell adhesion, spreading, proliferation, and differentiation of SAOS-2 osteoblasts were also up-regulated after plasma treatment. Additionally, PEEK samples treated with O2 plasma demonstrated a higher degree of bioactivation than those treated with Ar.SignificancePlasma-modified PEEK based on FFF 3D printing technology was a feasible and prospective bone grafting material for bone/dental implants.  相似文献   
7.
目的 对2019—2021年天津市人民医院贝伐珠单抗的临床应用情况进行评价,以期促进贝伐珠单抗超说明书用药的管理及其临床合理应用。方法 回顾性分析天津市人民医院2019年1月—2021年12月使用贝伐珠单抗患者的用药信息,根据说明书及指南评价其应用的合理性。结果 共收集1 313例患者(6 134次医嘱),通过适应症、治疗方案、用法用量3个方面评价应用合理性。结果 显示,存在适应症不适宜情况占比0.07%,用法用量不适宜情况占比4.77%,其中包括给药浓度不适宜(1.21%)、给药途径不适宜(0.23%)、与手术间隔时间不适宜(3.33%)。结论 天津市人民医院贝伐珠单抗的临床应用基本符合国内外说明书及指南要求,但也存在一定的超说明书用药情况。医院及临床药师应持续规范抗肿瘤药物超说明书使用的管理,促进抗肿瘤药物的合理应用。  相似文献   
8.
《Drug discovery today》2022,27(9):2425-2439
Cancer is one of the major causes of mortality, accounting for ~ 9.5 million deaths globally in 2018. The spectrum of conventional treatment for cancer includes surgery, chemotherapy and radiotherapy. Recently, cold plasma therapy surfaced as a novel technique in the treatment of cancer. The FDA approval of the first trial for the use of cold atmospheric plasma (CAP) in cancer therapy in 2019 is evidence of this. This review highlights the mechanisms of action of CAP. Additionally, its applications in anticancer therapy have been reviewed. In summary, this article will introduce the readers to the exciting field of plasma oncology and help them understand the current status and prospects of plasma oncology.  相似文献   
9.
PurposeTo assess the safety and tolerability of a vandetanib-eluting radiopaque embolic (BTG-002814) for transarterial chemoembolization (TACE) in patients with resectable liver malignancies.Materials and MethodsThe VEROnA clinical trial was a first-in-human, phase 0, single-arm, window-of-opportunity study. Eligible patients were aged ≥18 years and had resectable hepatocellular carcinoma (HCC) (Child-Pugh A) or metastatic colorectal cancer (mCRC). Patients received 1 mL of BTG-002814 transarterially (containing 100 mg of vandetanib) 7–21 days prior to surgery. The primary objectives were to establish the safety and tolerability of BTG-002814 and determine the concentrations of vandetanib and the N-desmethyl vandetanib metabolite in the plasma and resected liver after treatment. Biomarker studies included circulating proangiogenic factors, perfusion computed tomography, and dynamic contrast-enhanced magnetic resonance imaging.ResultsEight patients were enrolled: 2 with HCC and 6 with mCRC. There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. Surgical resection was not delayed. Vandetanib was present in the plasma of all patients 12 days after treatment, with a mean maximum concentration of 24.3 ng/mL (standard deviation ± 13.94 ng/mL), and in resected liver tissue up to 32 days after treatment (441–404,000 ng/g). The median percentage of tumor necrosis was 92.5% (range, 5%–100%). There were no significant changes in perfusion imaging parameters after TACE.ConclusionsBTG-002814 has an acceptable safety profile in patients before surgery. The presence of vandetanib in the tumor specimens up to 32 days after treatment suggests sustained anticancer activity, while the low vandetanib levels in the plasma suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies.  相似文献   
10.
目的探讨鼻呼出气一氧化氮(FnNO)动态变化对儿童慢性鼻窦炎(CRS)的疗效评估及潜在病因分析的临床意义。方法回顾2018—2020年深圳市儿童医院933例FnNO的检测结果,纳入其中随访FnNO变化的20例CRS住院患儿,根据过敏疾病史分为CRS伴过敏组(10例)和CRS不伴过敏组(10例)。应用Sunvou FnNO测定系统,采用鼻被动呼气+静音技术检测FnNO水平。结果① 20例患儿病程均>3个月,20例伴有慢性咳嗽,16例伴有鼻塞,10例伴有过敏史;②随访36个月,20例患儿治疗前后的FnNO值经比较差异具有统计学意义(150±164)ppb vs(337±280)ppb,P<0.05; ③CRS伴过敏组治疗后较治疗前FnNO明显升高,经比较差异具有统计学意义(136±116)ppb vs(519±280)ppb,P<0.01;而CRS不伴过敏组治疗前后的FnNO差异无统计学意义(164±206)ppb vs(156±120)ppb,P>0.05; ④10例CRS不伴过敏组患者中,4例FnNO水平持续降低,其中3例患儿确诊原发性纤毛运动障碍(PCD),多次复查FnNO均<77 ppb;1例确诊囊性纤维化(CF)。结论儿童CRS存在FnNO水平明显降低,可能与变态反应及鼻腔阻塞相关,而规律治疗后随访FnNO水平可逐渐趋于正常,少部分FnNO水平持续降低的患儿需警惕是否合并PCD、CF等基础疾病。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号